Search

Displaying results 191 - 200 of 3917 in total
  1. Drug

    Azathioprine

    go.drugbank.com/drugs/DB00993
    ApprovedInvestigational

    [L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]

  2. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    [L8237] This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213]

  3. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

  4. Drug

    Clopidogrel

    go.drugbank.com/drugs/DB00758
    ApprovedInvestigational

    [A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213] … [A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and

  5. Drug

    Glucosamine

    go.drugbank.com/drugs/DB01296
    Approved

    Osteoarthritis (OA) is a progressive and degenerative joint disease marked by loss of cartilage, bone changes, and synovial membrane inflammation.

    Mixtures: Bee Venom Joint And Bone Therapy Drops, Gluco-con capsulesCategories: Antiinflammatory and Antirheumatic Products, Non-Steroids
  6. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid … This approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887]

  7. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH). … [A263481] Sotatercept was approved by the European Commission on August 26, 2024.[L51549]

  8. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    [L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015] … [A199122] Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)

  9. Drug

    Terbutaline

    go.drugbank.com/drugs/DB00871
    ApprovedInvestigational

    [A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088]

  10. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.